| Ytd | -4.50% | |
| 1y | 148.59% |
| Open | 26.25 | Prev Close | 26.25 | Low | 25.10 | High | 26.29 | Mkt Cap | 1.50B |
| Vol | 197.86K | Avg Vol | 844.62K | EPS | -2.40 | P/E | -10.48 | Forward P/E | -8.98 |
| Beta | 0.77 | Short Ratio | 10.26 | Inst. Own | 115.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 30.06 | 200-d Avg | 29.28 | 1yr Est | 51.80 |
TYRA News
TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.69) per share which missed the analy
- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 d
Analysts change outlook on top Wall Street names. SNX, ORCL, EDU, ENS, SHOO, RH, have price target c
Wall Street analysts change outlook on top names, including upgrades/downgrades. Check our analyst r
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients li
Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary te
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcri
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stag
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's
'Top Wall Street analysts changed outlook on top names. See all rating changes incl. upgrades, d
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of
Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value ros
- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st
CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st
AquaBounty Technologies (NASDAQ: AQB - Get Free Report) and Tyra Biosciences (NASDAQ: TYRA - Get Fre
Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. Th
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) hit a new 52-week high during trading on Fri
CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st
CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-s
During Monday's trading, 1214 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
On Wednesday, 160 companies hit new 52-week lows.
During Tuesday's session, 454 stocks hit new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.